We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+24.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$2.23B
AUM Growth
+$544M
Cap. Flow
+$302M
Cap. Flow %
13.53%
Top 10 Hldgs %
63.09%
Holding
48
New
6
Increased
13
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$145M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$29.8M
3
PACB icon
Pacific Biosciences
PACB
+$25.9M
4
BLFS icon
BioLife Solutions
BLFS
+$21.4M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$19.3M

Top Sells

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$12.3M
2
BLUE
bluebird bio
BLUE
+$11.4M
3
VYGR icon
Voyager Therapeutics
VYGR
+$9.46M
4
CDXS icon
Codexis
CDXS
+$8.82M
5
ZYME icon
Zymeworks
ZYME
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 80.87%
2 Materials 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRS
26
DELISTED
Amyris Inc.
AMRS
$21.6M 0.97%
7,390,000
+2,040,624
+38% +$7.48M
CNST
27
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$19.9M 0.89%
980,000
– –
TSHA icon
28
Taysha Gene Therapies
TSHA
$1.66B
$18.4M 0.82%
+820,440
New +$19.3M
ALEC icon
29
Alector
ALEC
$168M
$17.4M 0.78%
1,650,000
+573,961
+53% +$9.28M
DMTK
30
DELISTED
DermTech, Inc. Common Stock
DMTK
$17.1M 0.76%
1,428,572
– –
ZLAB icon
31
Zai Lab
ZLAB
$2.05B
$15.8M 0.71%
190,000
– –
CELL
32
DELISTED
PhenomeX Inc. Common Stock
CELL
$15.3M 0.68%
+200,000
New +$12.7M
BMY.RT
33
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$14.1M 0.63%
6,250,000
+3,300,000
+112% +$9.42M
FULC icon
34
Fulcrum Therapeutics
FULC
$283M
$11.4M 0.51%
1,441,176
– –
SGMO
35
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.2M 0.46%
1,080,000
-375,000
-26% -$4.06M
IOVA icon
36
Iovance Biotherapeutics
IOVA
$1.93B
$9.55M 0.43%
+290,000
New +$8.89M
ILMN icon
37
Illumina
ILMN
$30B
$9.27M 0.42%
30,840
– –
BDTX icon
38
Black Diamond Therapeutics
BDTX
$99.7M
$8.75M 0.39%
289,395
– –
ORTX
39
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$7.69M 0.34%
187,000
+22,000
+13% +$1.14M
DYN icon
40
Dyne Therapeutics
DYN
$4.71B
$7.47M 0.33%
+370,000
New +$8.12M
TPTX
41
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$6.55M 0.29%
75,000
– –
ORIC icon
42
Oric Pharmaceuticals
ORIC
$1.1B
$6.29M 0.28%
251,515
– –
LEGN icon
43
Legend Biotech
LEGN
$3.68B
$4.31M 0.19%
139,661
+4,661
+3% +$157K
STOK icon
44
Stoke Therapeutics
STOK
$1.84B
$4.02M 0.18%
120,000
– –
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.33M 0.15%
65,000
– –
VYGR icon
46
Voyager Therapeutics
VYGR
$181M
– –
-750,000
Closed -$9.46M
ZYME icon
47
Zymeworks
ZYME
$1.6B
– –
-130,000
Closed -$4.69M
GRTS
48
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-1,850,373
Closed -$12.3M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Casdin Capital held 48 positions worth $2.23B, up 32% from $1.69B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital deployed $302M of net new capital in Q3 2020, opening 6 new positions and adding to 13 existing holdings. Its largest new stake was Relay Therapeutics: 3,808,894 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was bluebird bio, an estimated $11.4M trimmed.

  • Casdin Capital's largest Q3 2020 buy was Relay Therapeutics: 3,808,894 shares worth $162M.
  • Casdin Capital added most to Agios Pharmaceuticals in Q3 2020, an estimated $29.8M increase.
  • Casdin Capital's biggest Q3 2020 reduction was bluebird bio, cutting an estimated $11.4M.
  • Casdin Capital fully exited Gritstone bio, Inc. Common Stock in Q3 2020, selling an estimated $12.3M.
  • Casdin Capital's ten largest holdings make up 63% of its $2.23B portfolio in Q3 2020.
  • Casdin Capital opened 6 new positions and closed 3 in Q3 2020.
  • Casdin Capital's portfolio value rose 32% quarter-over-quarter to $2.23B.

Based on Casdin Capital's 13F filing for Q3 2020, filed 16 Nov 2020.